Dr. Brent Shane Rose, MD

Dr. Rose practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Rose's NPI, 1518250869, was assigned on May 19, 2011. Dr. Rose graduated from UC San Diego School of Medicine in 2010. Dr. Rose's Massachusetts license number on file is 248551.

Dr. Rose's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Rose's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Rose is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Rose to 3 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rose practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rose's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Rose's licenses on file in 2 states: Massachusetts and California.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, cancer radiation-upper GI, lung cancer radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Rose treats.

CMS data shows 1,588 Medicare services from Dr. Rose across 15 procedure codes in 2024, for 312 Medicare patients. Medicare paid $153,102 for them.

CMS counts 312 Medicare patients who saw Dr. Rose in 2024. The largest group is 65 to 74, with 148 patients. 75% of them have cancer, and 69% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rose's median patient age at 69, with 35% women.

In 2024, Dr. Rose wrote 146 Medicare Part D claims for 58 patients. 97% of them were for generic drugs. CMS names the drug for 102 of them, across 1 drug with 11 or more claims each, at $1,257 in total drug cost. In 2023, CMS named 76 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Rose for performance year 2024, reported as part of a group. Dr. Rose accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rose as offering telehealth.

Dmand AI links 150 papers to Dr. Rose, published from 2009 to 2025. 2021 was the busiest year, with 19. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Androgen Antagonists. Dr. Rose has published most often in Int J Radiat Oncol Biol Phys. Dr. Rose's most frequent co-authors are Rana Ramzi McKay, MD, James Don Murphy, MD and Loren K. Mell, MD.

Dmand AI links Dr. Rose to 3 clinical trials. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases. NRG Oncology sponsors the most, 2.

CMS Open Payments shows 21 general payments to Dr. Rose from 7 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $211.

Dr. Rose graduated from UC San Diego School of Medicine in 2010.

Dr. Rose is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.